Premium
Strategies to manage retinoblastoma in developing countries
Author(s) -
Chantada Guillermo L.,
Qaddoumi Ibrahim,
Canturk Serife,
Khetan Vikas,
Ma Zhigui,
Kimani Kahaki,
Yeniad Baris,
Sultan Iyad,
Sitorus Rita S.,
Tacyildiz Nurdan,
Abramson David H.
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22843
Subject(s) - medicine , retinoblastoma , developing country , socioeconomic status , disease , developed country , pediatrics , presentation (obstetrics) , environmental health , intensive care medicine , surgery , economic growth , population , biochemistry , chemistry , economics , gene
Survival of retinoblastoma is >90% in developed countries but there are significant differences with developing countries in stage at presentation, available treatment options, family compliance, and survival. In low‐income countries (LICs), children present with advanced disease, and the reasons are socioeconomic and cultural. In middle‐income countries (MICs), survival rates are better (>70%), but there is a high prevalence of microscopically disseminated extraocular disease. Programs for eye preservation have been developed, but toxicity‐related mortality is higher. Although effective treatment of microscopically extraocular disease improved the outcome, worldwide survival will be increased only by earlier diagnosis and better treatment adherence. Pediatr Blood Cancer 2011;56:341–348. © 2010 Wiley‐Liss, Inc.